BR9711734A - Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila - Google Patents

Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila

Info

Publication number
BR9711734A
BR9711734A BR9711734A BR9711734A BR9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A
Authority
BR
Brazil
Prior art keywords
alpha
monochlorochloride
metäxiimino
azabicyclo
alfa
Prior art date
Application number
BR9711734A
Other languages
English (en)
Portuguese (pt)
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beckman Corp filed Critical Smithkline Beecham Plc
Publication of BR9711734A publication Critical patent/BR9711734A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
BR9711734A 1996-09-12 1997-09-08 Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila BR9711734A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (fr) 1996-09-12 1997-09-08 Formulation a liberation lente de monohydrochlorure de [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile

Publications (1)

Publication Number Publication Date
BR9711734A true BR9711734A (pt) 1999-08-24

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711734A BR9711734A (pt) 1996-09-12 1997-09-08 Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila

Country Status (22)

Country Link
EP (1) EP0929301A2 (fr)
JP (1) JP2001500150A (fr)
KR (1) KR20000036039A (fr)
CN (2) CN1235544A (fr)
AR (1) AR008176A1 (fr)
AU (1) AU724086B2 (fr)
BR (1) BR9711734A (fr)
CA (1) CA2265661A1 (fr)
CO (1) CO5031291A1 (fr)
CZ (1) CZ83299A3 (fr)
GB (1) GB9619074D0 (fr)
HU (1) HUP9904401A3 (fr)
ID (1) ID19589A (fr)
IL (1) IL128781A0 (fr)
MA (1) MA24359A1 (fr)
NO (1) NO991194D0 (fr)
NZ (1) NZ334268A (fr)
PE (1) PE2499A1 (fr)
PL (1) PL332074A1 (fr)
TR (1) TR199900505T2 (fr)
WO (1) WO1998010762A2 (fr)
ZA (1) ZA978133B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
IL138192A0 (en) 1998-03-11 2001-11-25 Smithkline Beecham Plc Controlled release oral dosage forms
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
PA8578501A1 (es) 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
CA2520813C (fr) * 2003-04-25 2009-10-27 Mitsubishi Pharma Corporation Formulations de derives d'alkylene dioxybenzene a liberation prolongee servant d'antagonistes du recepteur 5-ht1a
DE602004002405T3 (de) * 2003-05-14 2013-06-20 Aptalis Pharma Limited Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
AU2005271193B2 (en) 2004-08-13 2011-11-24 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
RS52057B2 (sr) 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
EP1970056A1 (fr) * 2007-03-15 2008-09-17 Polichem S.A. Formules de dosages à libération retardée/pulsatile spécifique au temps
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48315A1 (en) * 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
CA2265661A1 (fr) 1998-03-19
CN1235544A (zh) 1999-11-17
AR008176A1 (es) 1999-12-09
ID19589A (id) 1998-07-23
PE2499A1 (es) 1999-03-24
AU4128897A (en) 1998-04-02
JP2001500150A (ja) 2001-01-09
MA24359A1 (fr) 1998-07-01
WO1998010762A3 (fr) 1998-06-04
HUP9904401A3 (en) 2001-03-28
KR20000036039A (ko) 2000-06-26
CN1446535A (zh) 2003-10-08
NZ334268A (en) 2000-10-27
PL332074A1 (en) 1999-08-30
AU724086B2 (en) 2000-09-14
ZA978133B (en) 1999-04-12
GB9619074D0 (en) 1996-10-23
WO1998010762A2 (fr) 1998-03-19
NO991194L (no) 1999-03-11
CO5031291A1 (es) 2001-04-27
EP0929301A2 (fr) 1999-07-21
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
TR199900505T2 (fr) 1999-06-21
NO991194D0 (no) 1999-03-11
CZ83299A3 (cs) 1999-08-11

Similar Documents

Publication Publication Date Title
EE9900540A (et) Omeprasooli ravimvorm
IS5721A (is) Pýróló [2,3-dl]pírimídín efnasambönd
PT1087970E (pt) Compostos pirrolo¬2,3-d|pirimidina
DE69804995T2 (de) Zyklonabscheider
EE04293B1 (et) Stabiilsed lüofiliseeritud ravimvormid
GB9823101D0 (en) Pharmaceutically active compounds
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
DK0839039T3 (da) Paroxetinpræparater med styret frigivelse
DK0891978T3 (da) 5H-Thiazol(3,2-a)pyrimidinderivativer
BR9711734A (pt) Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila
ATE321784T1 (de) Pthrp analogen
NO20002451D0 (no) Kondenserte pyrazinforbindelser
IS4848A (is) Lyfjafræðilega gagnleg efnasambönd
GB9823102D0 (en) Pharmaceutically active compounds
DE59804098D1 (de) Verdampferanordnung
PT964867E (pt) Antagonistas da taquicinima
ZA977809B (en) New pharmaceutically active compounds.
NO995033D0 (no) 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
IL131617A0 (en) 5,6,7-Trisubstituted-4-aminopyridol ¬2,3-d¾ pyrimidine compounds
ID16434A (id) Senyawa-senyawa 1,4-dihidropiridin
ZA977808B (en) New pharmaceutically active compounds.
DE29700340U1 (de) Lenkrolle
FR2762641B1 (fr) Serrure de meuble
FI973464A0 (fi) Foerfarande foer framstaellning av en ask med lock av en smal traedstam eller -rot
SE9704874D0 (sv) New pharmaceutically active compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.